CRISPR Therapeutics AG (CRSP) Retained Earnings (2015 - 2026)

CRISPR Therapeutics AG has disclosed Retained Earnings across 12 years of filings, most recently posting -$2.1 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$2.1 billion, down 37.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 billion (down 37.85% YoY), and the FY2025 annual result was -$1.9 billion, down 105945.16% from the prior year.
• Retained Earnings came in at -$2.1 billion for Q1 2026 at CRISPR Therapeutics AG, down from -$1.9 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $10.6 million in Q3 2024 to a low of -$2.1 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$9.4 million (2023), against an average of -$462.1 million.
• Across the five-year window, Retained Earnings surged 255.44% in 2024 and plunged 105945.16% in 2025, its largest moves.
• CRISPR Therapeutics AG's Retained Earnings stood at -$15.6 million in 2022, then jumped by 112.23% to $1.9 million in 2023, then fell by 3.82% to $1.8 million in 2024, then slumped by 105945.16% to -$1.9 billion in 2025, then retreated by 6.31% to -$2.1 billion in 2026.
• The last three Retained Earnings figures came in at -$2.1 billion (Q1 2026), -$1.9 billion (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.